(-0.07%) 5 465.35 points
(-0.06%) 39 087 points
(0.18%) 17 749 points
(-0.61%) $80.34
(-4.32%) $2.64
(-0.86%) $2 310.70
(-0.05%) $28.86
(2.30%) $1 009.10
(0.30%) $0.936
(0.73%) $10.68
(0.49%) $0.792
(-0.28%) $87.25
1.48% $ 5.84
Live Chart Being Loaded With Signals
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms...
Stats | |
---|---|
Volumen de hoy | 129 053 |
Volumen promedio | 669 787 |
Capitalización de mercado | 142.91M |
EPS | $-2.43 ( Q1 | 2024-03-31 ) |
Próxima fecha de ganancias | ( $-0.0600 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-5.23 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00700 (0.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-11-16 | Kay Mark A | Sell | 12 500 | Stock Option (right to buy) |
2022-11-16 | Enyedy Mark J | Sell | 12 500 | Stock Option (right to buy) |
2022-11-16 | Nacht Mariana | Sell | 100 000 | Stock Option (right to buy) |
2022-11-16 | Wyzga Michael S | Sell | 12 500 | Stock Option (right to buy) |
2022-11-16 | Chereau Frederic | Sell | 328 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
-97.72 |
Last 94 transactions |
Buy: 5 628 346 | Sell: 1 216 285 |
Volumen Correlación
LogicBio Therapeutics, Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
LogicBio Therapeutics, Correlación - Moneda/Commodity
LogicBio Therapeutics, Finanzas
Annual | 2023 |
Ingresos: | $287.00M |
Beneficio Bruto: | $59.00M (20.56 %) |
EPS: | $-13.36 |
FY | 2023 |
Ingresos: | $287.00M |
Beneficio Bruto: | $59.00M (20.56 %) |
EPS: | $-13.36 |
FY | 2021 |
Ingresos: | $5.41M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-1.240 |
FY | 2020 |
Ingresos: | $3.45M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-1.290 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
LogicBio Therapeutics,
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company\'s GeneRide technology is a new approach to precise gene insertion harnessing a cell\'s natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children\'s Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. As of November 15, 2022, LogicBio Therapeutics, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc..
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico